Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)

Valentina I. Petkov, Dave P. Miller, Nadia Howlader, Nathan Gliner, Will Howe, Nicola Schussler, Kathleen Cronin, Frederick L. Baehner, Rosemary D Cress, Dennis Deapen, Sally L. Glaser, Brenda Y. Hernandez, Charles F. Lynch, Lloyd Mueller, Ann G. Schwartz, Stephen M. Schwartz, Antoinette Stroup, Carol Sweeney, Thomas C. Tucker, Kevin C. WardCharles Wiggins, Xiao Cheng Wu, Lynne Penberthy, Steven Shak

Research output: Contribution to journalComment/debate

Abstract

In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes (n = 2,617) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1–3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the article stated “Patients with HR+, HER2-positive, node-negative…” this has been changed to “Patients with HR+, HER2-negative, node-negative…”. This has been corrected in the PDF and HTML versions of this paper.

Original languageEnglish (US)
Article number17
Journalnpj Breast Cancer
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17)'. Together they form a unique fingerprint.

  • Cite this

    Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R. D., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., ... Shak, S. (2018). Erratum to: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study (npj Breast Cancer, (2016), 2, 1, (16017), 10.1038/npjbcancer.2016.17). npj Breast Cancer, 4(1), [17]. https://doi.org/10.1038/s41523-018-0069-3